{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:03:55Z","timestamp":1788264235257,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02470-9","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:02:30Z","timestamp":1678860150000},"page":"2326-2338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness of Brentuximab Vedotin Versus Physician\u2019s Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada"],"prefix":"10.1007","volume":"40","author":[{"given":"David","family":"Elsea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-9897","authenticated-orcid":false,"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"issue":"16","key":"2470_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703\u201314.","journal-title":"Blood"},{"issue":"18","key":"2470_CR2","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1002\/cncr.30758","volume":"123","author":"FM Ghazawi","year":"2017","unstructured":"Ghazawi FM, Netchiporouk E, Rahme E, Tsang M, Moreau L, Glassman S, et al. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy. Cancer. 2017;123(18):3550\u201367.","journal-title":"Cancer"},{"issue":"20","key":"2470_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"10","key":"2470_CR4","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385.","journal-title":"Blood"},{"issue":"12","key":"2470_CR5","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1097\/PAS.0b013e3181bf677d","volume":"33","author":"JT Edinger","year":"2009","unstructured":"Edinger JT, Clark BZ, Pucevich BE, Geskin LJ, Swerdlow SH. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33(12):1860\u20138.","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"2470_CR6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/bjd.13849","volume":"173","author":"B Poligone","year":"2015","unstructured":"Poligone B, Querfeld C. Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary team. Br J Dermatol. 2015;173(4):1081\u20133.","journal-title":"Br J Dermatol"},{"issue":"8","key":"2470_CR7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/09546634.2018.1466026","volume":"29","author":"Y Tsang","year":"2018","unstructured":"Tsang Y, Gu T, Sharma G, Raspa S, Drake B 3rd, Tan H. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat. 2018;29(8):747\u201353.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"2470_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/ajh.24233","volume":"91","author":"RA Wilcox","year":"2016","unstructured":"Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151\u201365.","journal-title":"Am J Hematol"},{"key":"2470_CR9","unstructured":"Alberta Health Services. Clinical Practice Guideline LYHE-002 Version 12 2019 [updated September. Available from: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-lyhe002-lymphoma.pdf."},{"key":"2470_CR10","unstructured":"National Comprehensive Cancer Network. Primary Cutaneous Lymphomas (Version 2.2021) 2021 [updated Mar 4. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf."},{"issue":"Suppl 4","key":"2470_CR11","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Committee EG. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30\u201340.","journal-title":"Ann Oncol"},{"key":"2470_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"key":"2470_CR13","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH) Pan-Canadian Oncology Drug Review (pCODR) final clinical guidance report: brentuximab vedotin (Adcetris). 2020; https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10213BrentuximabVedotinpcALCLMF_fnCGR_NOREDACT_Post03Dec2020_final.pdf."},{"key":"2470_CR14","unstructured":"Pan-Canadian Oncology Drug Review. Initial recommendation for brentuximab vedotin (Adcetris) for primary cutaneous anaplastic large cell lymphoma mycosis fungoides. 2020 [Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/Reviews2020\/10213BrentuximabVedotinpcALCLMF_inRec_01Oct2020_Post_final.pdf."},{"issue":"10094","key":"2470_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366.","journal-title":"Lancet"},{"key":"2470_CR16","unstructured":"BC Cancer. BC Cancer Benefit Drug List 2020 [updated February 2020. Available from: http:\/\/www.bccancer.bc.ca\/systemic-therapy-site\/Documents\/Policy%20and%20Forms\/Benefit%20Drug%20List.pdf."},{"key":"2470_CR17","unstructured":"BresMed. Brentuximab vedotin CTCL KOL feedback. 2019."},{"issue":"6","key":"2470_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20131. Value Health. 2012;15(6):796\u2013803.","journal-title":"Value Health"},{"key":"2470_CR19","unstructured":"Lee KM, McCarron CE, Bryan S, Coyle D, Krahn M, McCabe C. Guidelines for the Economic Evaluation of Health Technologies: Canada \u2014 4th Edition 2017 [updated Mar. Available from: https:\/\/www.cadth.ca\/dv\/guidelines-economic-evaluation-health-technologies-canada-4th-edition."},{"key":"2470_CR20","unstructured":"Latimer N. NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials - Extrapolation with Patient Level Data 2011 [updated Mar 2013. Available from: http:\/\/nicedsu.org.uk\/technical-support-documents\/survival-analysis-tsd\/."},{"issue":"6","key":"2470_CR21","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","volume":"56","author":"P Swinburn","year":"2015","unstructured":"Swinburn P, Shingler S, Acaster S, Lloyd A, Bonthapally V. Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2015;56(6):1839\u201345.","journal-title":"Leuk Lymphoma"},{"key":"2470_CR22","doi-asserted-by":"crossref","unstructured":"Morris S. Reduced intensity allogeneic stem cell transplantation for advanced stage mycosis fungoides and S\u00e9zary syndrome. A Series of 53 patients from the UK. Eur J Cancer. 2018;101:S36.","DOI":"10.1016\/j.ejca.2018.07.302"},{"key":"2470_CR23","unstructured":"PDCI Market Access. End of Life Clinical Questionnaire. 2020."},{"issue":"6","key":"2470_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1524-4733.2010.00738.x","volume":"13","author":"I Chabot","year":"2010","unstructured":"Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health. 2010;13(6):837\u201345.","journal-title":"Value Health"},{"key":"2470_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2020.04.010","volume":"133","author":"R Dummer","year":"2020","unstructured":"Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, et al. Patient-reported quality of life in patients with relapsed\/refractory cutaneous T-cell lymphoma: results from the randomised phase III ALCANZA study. Eur J Cancer. 2020;133:120\u201330.","journal-title":"Eur J Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02470-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02470-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:13:09Z","timestamp":1682449989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02470-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02470-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}